David Ricks, Eli Lilly CEO (Evan Vucci/AP Images)

Eli Lil­ly: As do­nanemab fil­ing ap­proach­es, ex­ecs 'even more con­fi­den­t' in da­ta pack­age

Eli Lil­ly had a strong Q2, but un­sur­pris­ing­ly an­a­lysts don’t want to talk much about drugs al­ready ap­proved — their eyes are set firm­ly on Alzheimer’s hope­ful do­nanemab, a po­ten­tial block­buster in the mak­ing.

Lil­ly CEO David Ricks faced a wall of ques­tions Tues­day from an­a­lysts on the drug­mak­er’s Q2 earn­ings call look­ing to paint a pic­ture of Lil­ly’s hand as it pre­pares to file a BLA for do­nanemab lat­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.